Ani Pharms Drug Patent Portfolio
Ani Pharms owns 5 orange book drugs protected by 14 US patents with Innopran Xl having the least patent protection, holding only 1 patent. And Veregen with maximum patent protection, holding 5 patents. Given below is the list of Ani Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975047 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US12102662 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US12233105 | Methods for storing and warming purified corticotropin compositions | 27 Oct, 2043 | Active |
| US7858662 | Medicament for the treatment of viral skin and tumour diseases | 02 Oct, 2026 | Active |
| US9770406 | Medicament for the treatment of viral skin and tumour diseases | 12 Jul, 2025 | Active |
| US10434059 | Medicament for the treatment of viral skin and tumour diseases | 18 Nov, 2022 | Expired |
| US6500454 | Timed, sustained release systems for propranolol | 04 Oct, 2021 | Expired |
| US5795911 | Composition for treating Condyloma acuminata | 31 Oct, 2020 | Expired |
| US5968973 | Method for treating hyperplasia | 10 Apr, 2017 | Expired |
| US5721263 | Pharmaceutical composition for angiotensin II-mediated diseases | 24 Feb, 2015 | Expired |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases | 06 Jun, 2014 | Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them | 09 Jan, 2014 | Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them | 09 Jul, 2013 | Expired |
| US5196444 | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof | 04 Dec, 2012 | Expired |
Latest Legal Activities on Ani Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ani Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 13 Nov, 2023 | US10434059 |
|
Maintenance Fee Reminder Mailed
Critical
| 29 May, 2023 | US10434059 |
|
Expire Patent
Critical
| 30 Jan, 2023 | US7858662 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Aug, 2022 | US7858662 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jul, 2021 | US9770406 |
| Surcharge for Late Payment, Large Entity | 14 Jul, 2021 | US9770406 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 May, 2021 | US9770406 |
|
Recordation of Patent Grant Mailed
Critical
| 08 Oct, 2019 | US10434059 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 08 Oct, 2019 | US10434059 |
|
Email Notification
Critical
| 19 Sep, 2019 | US10434059 |
|
Issue Notification Mailed
Critical
| 18 Sep, 2019 | US10434059 |
|
Application Is Considered Ready for Issue
Critical
| 06 Sep, 2019 | US10434059 |
| Dispatch to FDC | 06 Sep, 2019 | US10434059 |
|
Issue Fee Payment Verified
Critical
| 19 Aug, 2019 | US10434059 |
|
Issue Fee Payment Received
Critical
| 19 Aug, 2019 | US10434059 |
Ani Pharms's Drug Patent Litigations
Ani Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2015, against patent number US9770406. The petitioner , challenged the validity of this patent, with Yunik Chang et al as the respondent. Click below to track the latest information on how companies are challenging Ani Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9770406 | September, 2015 |
Decision
(07 Feb, 2017)
| Yunik Chang et al | |
Ani Pharms's Family Patents
Ani Pharms Drug List
Given below is the complete list of Ani Pharms's drugs and the patents protecting them.
1. Atacand
Atacand is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5534534
(Pediatric)
| Pharmaceutical compositions for oral use and method of preparing them |
09 Jan, 2014
(11 years ago)
| Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them |
09 Jul, 2013
(11 years ago)
| Expired |
| US5196444
(Pediatric)
| 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
04 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atacand's drug page
2. Atacand Hct
Atacand Hct is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5721263 | Pharmaceutical composition for angiotensin II-mediated diseases |
24 Feb, 2015
(10 years ago)
| Expired |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases |
06 Jun, 2014
(10 years ago)
| Expired |
| US5534534
(Pediatric)
| Pharmaceutical compositions for oral use and method of preparing them |
09 Jan, 2014
(11 years ago)
| Expired |
| US5534534 | Pharmaceutical compositions for oral use and method of preparing them |
09 Jul, 2013
(11 years ago)
| Expired |
| US5196444
(Pediatric)
| 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
04 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atacand Hct's drug page
3. Innopran Xl
Innopran Xl is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6500454 | Timed, sustained release systems for propranolol |
04 Oct, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Innopran Xl's drug page
4. Purified Cortrophin Gel
Purified Cortrophin Gel is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975047 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(18 years from now)
| Active |
| US12102662 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(18 years from now)
| Active |
| US12233105 | Methods for storing and warming purified corticotropin compositions |
27 Oct, 2043
(18 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Purified Cortrophin Gel's drug page
5. Veregen
Veregen is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7858662 | Medicament for the treatment of viral skin and tumour diseases |
02 Oct, 2026
(1 year, 4 months from now)
| Active |
| US9770406 | Medicament for the treatment of viral skin and tumour diseases |
12 Jul, 2025
(2 months from now)
| Active |
| US10434059 | Medicament for the treatment of viral skin and tumour diseases |
18 Nov, 2022
(2 years ago)
| Expired |
| US5795911 | Composition for treating Condyloma acuminata |
31 Oct, 2020
(4 years ago)
| Expired |
| US5968973 | Method for treating hyperplasia |
10 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veregen's drug page